Cheng, J; Kozikowski, AP. We need 2C but not 2B: Developing serotonin 2C (5-HT2C) receptor agonists for the treatment of CNS disorders ChemMedChem, 1 Dec 2015, 10 (12), 1963–1967. 1.1 MB. https://doi.org/10.1002/cmdc.201500437 #16
Cheng, J; Giguère, PM; Onajole, OK; Lv, W; Gaisin, A; Gunosewoyo, H; Schmerberg, CM; Pogorelov, VM; Rodriguiz, RM; Vistoli, G; Wetsel, WC; Roth, BL; Kozikowski, AP. Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents J. Med. Chem., 26 Feb 2015, 58 (4), 1992–2002. 1.9 MB. https://doi.org/10.1021/jm5019274 #16b MS,NMR
Zhang, G; Cheng, J; McCorvy, JD; Lorello, PJ; Caldarone, BJ; Roth, BL; Kozikowski, AP. Discovery of N-substituted (2-phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications J. Med. Chem., 27 Jul 2017, 60 (14), 6273–6288. 3.5 MB. https://doi.org/10.1021/acs.jmedchem.7b00584 #11 MS,NMR
Cheng, J; Giguere, PM; Schmerberg, CM; Pogorelov, VM; Rodriguiz, RM; Huang, X; Zhu, H; McCorvy, JD; Wetsel, WC; Roth, BL; Kozikowski, AP. Further advances in optimizing (2-phenylcyclopropyl)methylamines as novel serotonin 2C agonists: Effects on hyperlocomotion, prepulse inhibition, and cognition models J. Med. Chem., 28 Jan 2016, 59 (2), 578–591. 2.9 MB. https://doi.org/10.1021/acs.jmedchem.5b01153 #5 MS,NMR